I-Flow welcomes AcryMed as 2007 growth exceeds forecasts
This article was originally published in Clinica
I-Flow, the Lake Forest, California-based manufacturer of pain management systems, said total sales for 2007 outpaced its expectations by increasing 24% to $116.5m. The company had previously forecast annual sales growth to be 20%. Sales of its regional anaesthesia products, which provide site-specific pain management, were also better than expected, growing 32% to $89.6m. In conjunction with its preliminary 2007 results, the firm announced the closing of its acquisition of AcryMed. I-Flow inked a $25m all-cash deal to buy the Beaverton, Oregon-based developer of silver-based infection control and wound healing technologies in December 2007 (see Clinica No 1287, p 12).
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.